Global Vascular Disrupting Agents Market

Report ID : 1299 | Published : 2022-07-06 | Pages: | Format: PDF/EXCEL

Vascular Disrupting Agents Market is valued at US$ 79.75 Mn in 2021 with a CAGR of 46.7% during a forecast period of 2022-2030. Vascular disrupting agents (VDAs) are a novel family of medications that target the existing tumour vasculature and cause tumour necrosis. As the world's population has aged, so has the global burden of cancer morbidity and mortality. Cancer is the primary or second leading cause of death among persons under the age of 70 in 112 of 183 countries, according to World Health Organization estimates in 2019. Vascular disrupting agents are the medications utilized in tumour vascular disrupting treatment (VDAs). VDAs can specifically target tumour vasculature via several mechanisms, inhibiting blood flow within tumours and causing widespread secondary necrosis while leaving normal tissues largely unscathed. These agents are used to treat various cancer types such as thyroid cancer, liver cancer, ovarian cancer, and colorectal cancer.

Factors driving the growth of the vascular disrupting agents market include the high prevalence rate of cancer, rising geriatric population, increasing demand for advanced cancer therapy options, growing public awareness about novel therapy treatments, increasing government expenditure for cancer therapy research and development, expiry of patents for various drugs,  and the changing lifestyle standards. Furthermore, pharmaceutical companies are investing more in cancer research due to the growing list of risk factors and cancer-causing agents of existing anticancer therapies, thereby creating growth opportunities for the vascular disrupting agents market. However, the high cost of target therapies and the lack of availability of safety data may restrict the market growth in the future. 

The vascular disrupting agents market is classified based on indications, therapeutic area,  molecules, therapy, route of administration, product, and region. Based on the indications, the market comprises chemotherapy-induced neutropenia, glioblastoma, liver cancer, mesothelioma, non-small cell lung cancer, prostate cancer, ovarian cancer, renal pelvis, and ureter cancer. The market is segmented into hematological malignancies and solid tumors by therapeutic area. By molecules, the market is divided into tubulin binding agents, flavonoids, and ligand-directed agents. The Tubulin Binding Agents and Flavonoids segments are anticipated to expand over the forecast period as the small molecules are majorly used in the pipeline. In terms of therapy, the market is bifurcated into mono and combination. by route of administration, the market is classified into oral and intravenous. The product segment is categorized into Bavituximab, Icaritin, NGR-TNF, Padeliporfin, Plinabulin, VB-111, and others. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

North America will likely hold the highest share of this market in the next few years due to the well-established healthcare infrastructures, growing elderly population, and rising patient awareness regarding the benefits of new targeted therapies.

Few key players operating in the vascular disrupting agents market are AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VBL Therapeutics (Israel), Steba biotech (US), BeyondSpring Pharmaceuticals (US), Immune Pharmaceuticals (US), Nereus Pharmaceuticals (US), Madrigal Pharmaceuticals, Inc. (US), Celgene Corporation (US), Bionomics Ltd. (Australia), Lees Pharmaceutical Holdings. (Hong Kong), and others.

Companies Mentioned

  • AGC Biologics
  • Avid Bioservices
  • Bionomics
  • Beijing Shenogen Biomedical
  • Mateon Therapeutics
  • Myrexis
  • VBL Therapeutics
  • Steba biotech
  • BeyondSpring Pharmaceuticals
  • Immune Pharmaceuticals
  • Nereus Pharmaceuticals
  • Madrigal Pharmaceuticals, Inc.
  • Celgene Corporation
  • Bionomics Ltd.
  • Lees Pharmaceutical Holdings.
  • Other Prominent Players

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Vascular Disrupting Agents Market Snapshot

Chapter 4. Global Vascular Disrupting Agents Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Indication, Estimates & Trend Analysis

5.1. By Indications, & Market Share, 2019 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Indications:

5.2.1. Chemotherapy-Induced Neutropenia

5.2.2. Glioblastoma

5.2.3. Liver Cancer

5.2.4. Mesothelioma

5.2.5. Non-Small Cell Lung Cancer

5.2.6. Prostate Cancer

5.2.7. Ovarian Cancer

5.2.8. Renal Pelvis

5.2.9. Ureter Cancer

Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis

6.1. By Therapeutic Area & Market Share, 2019 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Therapeutic Area:

6.2.1. Hematological Malignancies

6.2.2. Solid Tumors

Chapter 7. Market Segmentation 3: By Molecule Estimates & Trend Analysis

7.1. By Molecule & Market Share, 2019& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Molecule:

7.2.1. Tubulin Binding Agents

7.2.2. Flavonoids

7.2.3. Ligand-Directed Agents

Chapter 8. Market Segmentation 4: By Therapy Estimates & Trend Analysis

8.1. By Therapy & Market Share, 2019& 2030

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Therapy

8.2.1. Mono

8.2.2. Combination

Chapter 9. Market Segmentation 5: By Route of Administrations Estimates & Trend Analysis

9.1. By Route of Administrations & Market Share, 2019& 2030

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Route of Administrations:

9.2.1. Oral

9.2.2. Intravenous

Chapter 10. Market Segmentation 6: By Products Estimates & Trend Analysis

10.1. By Products & Market Share, 2019 & 2030

10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Products:

10.2.1. Bavituximab

10.2.2. Icaritin

10.2.3. NGR-TNF

10.2.4. Padeliporfin

10.2.5. Plinabulin

10.2.6. VB-111

10.2.7. Other Products

Chapter 11. Vascular Disrupting Agents Market Segmentation 7: Regional Estimates & Trend Analysis

11.1. North America

11.1.1. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Indications, 2022-2030

11.1.2. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2022-2030

11.1.3. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Molecule, 2022-2030

11.1.4. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2022-2030

11.1.5. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2022-2030

11.1.6. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2022-2030

11.1.7. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by country, 2022-2030

11.2. Europe

11.2.1. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2022-2030

11.2.2. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2022-2030

11.2.3. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2022-2030

11.2.4. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2022-2030

11.2.5. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2022-2030

11.2.6. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2022-2030

11.2.7. Europe Vascular Disrupting Agents Market revenue (US$ Million) by country, 2022-2030

11.3. Asia Pacific

11.3.1. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2022-2030

11.3.2. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2022-2030

11.3.3. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2022-2030

11.3.4. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2022-2030

11.3.5. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2022-2030

11.3.6. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2022-2030

11.3.7. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) by country, 2022-2030

11.4. Latin America

11.4.1. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2022-2030

11.4.2. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2022-2030

11.4.3. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2022-2030

11.4.4. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2022-2030

11.4.5. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2022-2030

11.4.6. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2022-2030

11.4.7. Latin America Vascular Disrupting Agents Market revenue (US$ Million) by country, 2022-2030

11.5. Middle East & Africa

11.5.1. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2022-2030

11.5.2. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2022-2030

11.5.3. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2022-2030

11.5.4. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2022-2030

11.5.5. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2022-2030

11.5.6. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2022-2030

11.5.7. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) by country, 2022-2030

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances

12.2. Company Profiles 

12.2.1. AGC Biologics

12.2.2. Avid Bioservices

12.2.3. Bionomics

12.2.4. Beijing Shenogen Biomedical

12.2.5. Mateon Therapeutics

12.2.6. Myrexis

12.2.7. VBL Therapeutics

12.2.8. Steba biotech

12.2.9. BeyondSpring Pharmaceuticals

12.2.10. Immune Pharmaceuticals

12.2.11. Nereus Pharmaceuticals

12.2.12. Madrigal Pharmaceuticals, Inc.

12.2.13. Celgene Corporation

12.2.14. Bionomics Ltd.

12.2.15. Lees Pharmaceutical Holdings.

12.2.16. Other Prominent Players

Global Vascular Disrupting Agents Market, by Indications, 2020-2030 (Valu US$ Mn)

  • Chemotherapy-Induced Neutropenia
  • Glioblastoma
  • Liver Cancer
  • Mesothelioma
  • Non-Small Cell Lung Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Renal Pelvis
  • Ureter Cancer

Global Vascular Disrupting Agents Market, by Therapeutic Area, 2020-2030 (Valu US$ Mn)

  • Hematological Malignancies
  • Solid Tumors

Global Vascular Disrupting Agents Market, by Molecules, 2020-2030 (Value US$ Mn)

  • Tubulin Binding Agents
  • Flavonoids
  • Ligand-Directed Agents

Global Vascular Disrupting Agents Market, by Therapy, 2020-2030 (Valu US$ Mn)

  • Mono
  • Combination

Global Vascular Disrupting Agents Market, by Route of Administration, 2020-2030 (Value US$ Mn)

  • Oral
  • Intravenous

Global Vascular Disrupting Agents Market, by Product, 2020-2030 (Valu US$ Mn)

  • Bavituximab
  • Icaritin
  • NGR-TNF
  • Padeliporfin
  • Plinabulin
  • VB-111
  • Others

Global Vascular Disrupting Agents Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Vascular Disrupting Agents Market?

valued at US$ 79.75 Mn in 2021

CAGR of 46.7% during a forecast period of 2022-2030.

Our Clients